SCHEMBL30584903

SCHEMBL30584903

O=C(NCc1cccnc1)C1CCN(c2nc(-c3ccncc3)no2)CC1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.56
▸ TSHR P16473 3/20 0.56
▸ CYP2C9 P11712 2/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ LMNA P02545 2/20 0.55
▸ KMT2A Q03164 4/20 0.53
▸ MAPT P10636 3/20 0.52
▸ MAPK1 P28482 2/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ CYP3A4 P08684 1/20 0.51
▸ CYP2D6 P10635 1/20 0.51
▸ HTT P42858 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31546349 0.93 ALDH1A1 (0.54) ALDH1A1TSHRCYP2C9CYP2C19LMNA
SCHEMBL25434291 0.92 HTT (0.60) ALDH1A1TSHRCYP2C9CYP2C19LMNA
SCHEMBL31546388 0.92 HTT (0.60) ALDH1A1TSHRCYP2C9CYP2C19LMNA
SCHEMBL30584837 0.89 LMNA (0.62) ALDH1A1LMNAKMT2AMAPTMEN1
SCHEMBL25438262 0.89 LMNA (0.62) ALDH1A1LMNAKMT2AMAPTMEN1
SCHEMBL30584862 0.85 TSHR (0.59) ALDH1A1TSHRCYP2C9CYP2C19LMNA
SCHEMBL25432654 0.83 KMT2A (0.54) ALDH1A1TSHRCYP2C9CYP2C19LMNA
SCHEMBL30584943 0.83 KMT2A (0.54) ALDH1A1TSHRCYP2C9CYP2C19LMNA
SCHEMBL31546346 0.81 LMNA (0.66) ALDH1A1LMNAKMT2AMAPTMEN1
SCHEMBL30584890 0.79 LMNA (0.65) LMNAKMT2AMAPTMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 — — EP disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 ALDH1A1 4471/4885TSHR 4347/4885CYP2C9 4869/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 ALDH1A1 4471/4885TSHR 4347/4885CYP2C9 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback